Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival

Cancer

Volumn 101, Issue 1, 2004, Pages 3-27

  Jemal, Ahmedin ^a   Clegg, Limin X ^b   Ward, Elizabeth ^a   Ries, Lynn A G ^b   Wu, Xiaocheng ^c,d   Jamison, Patricia M ^e   Wingo, Phyllis A ^e   Howe, Holly L ^d   Anderson, Robert N ^f   Edwards, Brenda K ^b  

^a AMERICAN CANCER SOCIETY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d N Amer Assoc Ctrl Cancer Regis   (United States)

^e NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^f NATIONAL CENTER FOR HEALTH STATISTICS   (United States)

Author keywords

Cancer; Incidence; Mortality; National Program of Cancer Registries (NPCR); North American Association of Central Cancer Registries (NAACCR); Surveillance, Epidemiology, and End Results (SEER); Survival; U.S.; Vital statistics

Indexed keywords

BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; CHILDHOOD CANCER; COLORECTAL CANCER; ETHNIC DIFFERENCE; HUMAN; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; MELANOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; REVIEW; STATISTICAL ANALYSIS; UNITED STATES;

AMERICAN CANCER SOCIETY; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CONTINENTAL POPULATION GROUPS; FEMALE; HUMANS; INCIDENCE; MALE; NEOPLASMS; REGISTRIES; SEER PROGRAM; SURVIVAL RATE; UNITED STATES;

EID: 3042628862     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20288     Document Type: Review

References (141)

1. Wingo P, Ries L, Rosenberg H, Miller D, Edwards B. Cancer incidence and mortality, 1973-1995: a report card for the U.S. Cancer. 1998;82:1197-1207.
2. Wingo P, Ries L, Giovino G, et al. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst. 1999;91:675-690.
3. Ries L, Wingo P, Miller D, et al. Annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer. 2000;88:2398-2424.
4. Howe H, Wingo P, Thun M, et al. Annual report to the nation on the status of cancer, 1973 through 1998, featuring cancers with increasing trends. J Natl Cancer Inst. 2001; 93:824-842.
5. Edwards B, Howe H, Ries L, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer. 2002;94:2766-2792.
6. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003;95:1276-1299.
7. Howe HL, Edwards BK, Young JL, et al. A vision for cancer incidence surveillance in the United States. Cancer Causes Control. 2003;14:663-672.
8. Fritz A, Percy C, Jack A, et al. International classification of diseases of oncology. Geneva: World Health Organization, 2000.
9. Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1975-2001. Available from URL http://www. seer.cancer.gov/csr/1975-2001/ [accessed May 5, 2004].
10. Kramarova E, Stiller CA. The international classification of childhood cancer. Int J Cancer. 1996;68:759-765.
11. Shambaugh EM, Weiss MA, Axtell LM, Ryan RF, Platz CE. Summary staging guide for the cancer Surveillance, Epidemiology, and End Results (SEER) reporting program. Bethesda, MD: National Institutes of Health, 1983.
12. Young JL Jr., Roffers SD, Ries LAG, Fritz AG, Hurlbut AA, editors. SEER summary staging manual-2000: codes and coding instructions, Bethesda (MD): National Cancer Institute; 2001 NIH Pub. No. 01-4969.
13. National Center for Health Statistics. Vital statistics of the United States, 1950-1999, Volume II. Mortality, Parts A and B. Washington, DC: Public Health Service, 2001.
14. U.S. Department of Health Education and Welfare and National Center for Health Statistics. Manual of the international statistical classification of diseases, injuries, and causes of death, adapted for use in the United States. 8th revision. Washington, DC: Public Health Service, 1967.
15. World Health Organization. Manual of the international statistical classification of diseases, injuries, and causes of death, based on the recommendations of the ninth revision conference. Geneva: World Health Organization, 1977.
16. World Health Organization. International statistical classification of diseases and related health problems. 10th revision. Geneva: World Health Organization, 1992.
17. Anderson RN, Minino AM, Hoyert DL, Rosenberg HM. Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates. Natl Vital Stat Rep. 2001; 49:1-32.
18. Surveillance, Epidemiology, and End Results (SEER) Program. SEER 1975-2001. SEER*Stat Database: Incidence-SEER 9 Regs, Nov 2003 Sub (1973-2001) <19 Age Groups. Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, 2004.
19. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335-351.
20. Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002;94: 1537-1545.
21. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
22. Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) program population-based study. Arch Intern Med. 2002;162:1985-1993.
23. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187-220.
24. SAS Institute Inc. SAS/STAT user's guide. Version 6. Cary, NC: SAS Institute, Inc., 1989.
25. Jemal A, Ward E, Anderson RN, Thun MJ. Influence of rules from the Tenth Revision of the International Classification of Diseases on U.S. cancer mortality trends. J Natl Cancer Inst. 2003;95:1727-1728.
26. Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med. 1993;328:1237-1243.
27. Patz EF Jr., Goodman PC, Bepler G. Screening for lung cancer. N Engl J Med. 2000;343:1627-1633.
28. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312:1604-1608.
29. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54:78-93.
30. Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003;97:1528-1540.
31. Smedley B, Stith AY, Nelson AR. Unequal treatment: confronting racial and ethnic disparities in health care. Washington, DC: The National Academies Press, 2003:764.
32. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002;287:2106-2113.
33. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94: 334-357.
34. Legler JM, Feuer EJ, Potosky AL, Merrill RM, Kramer BS. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. Cancer Causes Control. 1998;9:519-527.
35. Hsing AW, Devesa SS. Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev. 2001;23:3-13.
36. Alavanja MC, Samanic C, Dosemeci M, et al. Use of agricultural pesticides and prostate cancer risk in the Agricultural Health Study cohort. Am J Epidemiol. 2003;157:800-814.
37. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer - part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91:1017-1024.
38. Guileyardo JM, Johnson WD, Welsh RA, Akazaki K, Correa P. Prevalence of latent prostate carcinoma in two U.S. populations. J Natl Cancer Inst. 1980;65:311-316.
39. Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons (France). Int J Cancer. 1977;20:680-688.
40. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94: 981-990.
41. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003;95:981-989.
42. Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology. 2002;60:7-11; discussion, 11-12.
43. Smith M, Peto R. Prostate cancer deaths dropping in Europe, US, due to hormone therapy. The European Cancer Conference, Copenhagen (Denmark). Oncology Times XXV, 2003 October 25; page 24.
44. Kupelian PA, Buchsbaum JC, Elshaikh MA, Reddy CA, Klein EA. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome. Int J Radiat Oncol Biol Phys. 2003;57:629-634.
45. Bennett CL, Ferreira MR, Davis TC, et al. Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clin Oncol. 1998;16:3101-3104.
46. Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol. 1995;13:93-100.
47. Burns DM, Lee L, Shen LZ, et al. Cigarette smoking in the United States. In: Burns DM, Garfinkel L, Samet JM, editors. Changes in cigarette-related disease risks and their implication for prevention and control. Monograph 8. Volume 2. Bethesda, MD: National Cancer Institute, 1997:13-112.
48. Orzechowski W, Walker R. The tax burden on tobacco: historical compilation 2001: impact and opportunity. Arlington, VA: Orzechowski and Walker, 2002.
49. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379-392.
50. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351-360.
51. Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. N Engl J Med. 1999;341:1198-1205.
52. Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks JC. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol. 2002;20:1786-1792.
53. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
54. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res. 1993;53:1322-1327.
55. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in post-menopausal women. N Engl J Med. 2004;350:991-1004.
56. Schottenfeld D, Winawer SJ. Cancer of the large intestine. In: Schottenfeld D, Fraumeni JF Jr., editors. Cancer epidemiology and prevention. New York: Oxford University Press, 1996:813-840.
57. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352-358.
58. Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol. 1989;7:1447-1456.
59. Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001;93:850-857.
60. Hodgson DC, Fuchs CS, Ayanian JZ. Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer. J Natl Cancer Inst. 2001;93:501-515.
61. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002; 20:1192-1202.
62. Schrag D, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB. Who gets adjuvant treatment for stage II and III rectal cancer? Insight from Surveillance, Epidemiology, and End Results - Medicare. J Clin Oncol. 2001;19:3712-3718.
63. Cooper GS, Yuan Z, Landefeld CS, Rimm AA. Surgery for colorectal cancer: race-related differences in rates and survival among Medicare beneficiaries. Am J Public Health. 1996;86:582-586.
64. Ghafoor A, Jemal A, Ward E, Cokkinides V, Smith R, Thun MJ. Trends in breast cancer by race and ethnicity. CA Cancer J Clin. 2003;53:342-355.
65. Harlan LC, Abrams J, Warren JL, Clegg L, Stevens J, Ballard-Barbash R. Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol. 2002;20: 1809-1817.
66. Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst. 2002;94:1626-1634.
67. American Cancer Society. Cancer facts & figures 2004. Atlanta: American Cancer Society, Inc., 2004.
68. Griggs JJ, Sorbero ME, Stark AT, Heininger SE, Dick AW. Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Res Treat. 2003;81:21-31.
69. Mandelblatt JS, Kerner JF, Hadley J, et al. Variations in breast carcinoma treatment in older Medicare beneficiaries: is it black or white. Cancer. 2002;95:1401-1414.
70. Newman LA, Kuerer HM, Harper T, et al. Special considerations in breast cancer risk and survival. J Surg Oncol. 1999;71:250-260.
71. Bradley CJ, Given CW, Roberts C. Disparities in cancer diagnosis and survival. Cancer. 2001;91:178-188.
72. Chu KC, Lamar CA, Freeman HP. Racial disparities in breast carcinoma survival rates: separating factors that affect diagnosis from factors that affect treatment. Cancer. 2003;97:2853-2860.
73. Eley JW, Hill HA, Chen VW, et al. Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. JAMA. 1994; 272:947-954.
74. Chen VW, Correa P, Kurman RJ, et al. Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarkers Prev. 1994;3:127-135.
75. Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst. 1994;86:705-712.
76. Hershman D, Weinberg M, Rosner Z, et al. Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer. J Natl Cancer Inst. 2003;95:1545-1548.
77. Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst. 2002;94:1204-1210.
78. Freedman AS, Nadler LM. Non-Hodgkin's lymphomas. In: Holland JF, Frei E, editors. Cancer medicine 6. Volume 2. Hamilton, Ontario: BC Decker Inc., 2003:2189-2210.
79. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
80. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16:2780-2795.
81. Chen MG, Prosnitz LR, Gonzalez-Serva A, Fischer DB. Results of radiotherapy in control of stage I and II non-Hodgkin's lymphoma. Cancer. 1979;43:1245-1254.
82. McLaughlin P, Fuller LM, Velasquez WS, Sullivan-Halley JA, Butler JJ, Cabanillas F. Stage I-II follicular lymphoma. Treatment results for 76 patients. Cancer. 1986;58:1596-1602.
83. Ezdinli EZ, Harrington DP, Kucuk O, Silverstein MW, Anderson J, O'Connell MI. The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma. Cancer. 1987;60:156-160.
84. Jones SE, Grozea PN, Miller TP, et al. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group Study. J Clin Oncol. 1985;3:1318-324.
85. Young RC, Johnson RE, Canellos GP, et al. Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination. Cancer Treat Rep. 1977;61:1153-1159.
86. DeVita VT Jr., Canellos GP, Chabner B, Schein P, Hubbard SP, Young RC. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet. 1975;1:248-250.
87. Coltman C. CHOP is curative in thirty percent of patients with large cell lymphoma: a twelve year Southwest Oncology Group follow-up. Volume 71. New York: Park Row, 1986.
88. Blum KA, Bartlett NL. Antibodies for the treatment of diffuse large cell lymphoma. Semin Oncol. 2003;30:448-456.
89. Philip T, Guglielmi C, Chauvin F. Autologous bone marrow transplantation versus conventional chemotherapy (DHAP) in relapsed non-Hodgkin's lymphoma: final analysis of the PARMA randomized study [abstract]. Proc Am Soc Clin Oncol. 1995;14:390.
90. Blay J, Gomez F, Sebban C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood. 1998;92:3562-3568.
91. Jemal A, Devesa SS, Hartge P, Tucker MA. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst. 2001;93:678-683.
92. Armstrong BK, English DR. Cutaneous malignant melanoma. In: Schottenfeld D, Fraumeni JF Jr., editors. Cancer epidemiology and prevention. New York: Oxford University Press, 1996:1521.
93. Hall HI, Miller DR, Rogers JD, Bewerse B. Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol. 1999;40:35-42.
94. Morton DL. Current management of malignant melanoma. Ann Surg. 1990;212:123-124.
95. Morton DL, Foshag LJ, Hoon DS, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg. 1992;216:463-482.
96. Agarwala S. Improving survival in patients with high-risk and metastatic melanoma: immunotherapy leads the way. Am J Clin Dermatol. 2003;4:333-346.
97. Garcia-Manero GKH, Schiffer CA. Adult acute lymphocytic leukemia. In: Holland JF, Frei E, editors. Cancer medicine 6. Volume 2. Hamilton, Ontario: BC Decker Inc., 2003: 2125-2134.
98. Gottlieb AJ, Weinberg V, Ellison RR, et al. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B. Blood. 1984;64:267-274.
99. Schiffer CA. Acute myeloid leukemia in adults. In: Holland JF, Frei E, editors. Cancer medicine 6. Volume 2. Hamilton, Ontario: BC Decker Inc., 2003:2095-2116.
100. Silver RT. Chronic myeloid leukemia. In: Holland JF, Frei E, editors. Cancer medicine 6. Volume 2. Hamilton, Ontario: BC Decker Inc., 2003:2117-2124.
101. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
102. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
103. Kadan-Lottick NS, Ness KK, Bhatia S, Gurney JG. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. JAMA. 2003;290:2008-2014.
104. Carroll WL. Race and outcome in childhood acute lymphoblastic leukemia. JAMA. 2003;290:2061-2063.
105. Pui CH, Sandlund JT, Pei D, et al. Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA. 2003;290:2001-2007.
106. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281:1628-1631.
107. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998;51: 203-205.
108. Leslie JA, Prihoda T, Thompson IM. Serendipitous renal cell carcinoma in the post-CT era: continued evidence in improved outcomes. Urol Oncol. 2003;21:39-44.
109. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord. 1998;22: 39-47.
110. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-1727.
111. Chow WH, Gridley G, Fraumeni JF Jr., Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343:1305-1311.
112. Espey DK, Paisano RE, Cobb N. Cancer mortality among American Indians and Alaska Natives: regional differences, 1994-1998. Rockville, MD: Indian Health Service, 2003.
113. Richie JP, Kantoff PW. Renal cell carcinoma. In: Holland JF, Frei E, editors. Cancer medicine 6. Volume 2. Hamilton, Ontario: BC Decker Inc., 2003:1675-1682.
114. Balis F, Holcenberg J, Blaney S. General principles of chemotherapy. In: Pizzo P, Poplack D, editors. Principles and practice of pediatric oncology. Philadelphia: Lippincott Williams & Wilkins, 2002:237-308.
115. Liu L, Krailo M, Reaman GH, Bernstein L. Childhood cancer patients' access to cooperative group cancer programs: a population-based study. Cancer. 2003;97:1339-1345.
116. Reaman G. Pediatric oncology: principles and practice. In: Holland JF, Frei E, editors. Cancer medicine 6. Volume 2. Hamilton, Ontario: BC Decker Inc., 2003:2291-2293.
117. Bleyer WA, Tejeda H, Murphy SB, et al. National cancer clinical trials: children have equal access; adolescents do not. J Adolesc Health. 1997;21:366-373.
118. Mandelblatt J, Andrews H, Kao R, Wallace R, Kerner J. The late-stage diagnosis of colorectal cancer: demographic and socioeconomic factors. Am J Public Health. 1996;86:1794-1797.
119. Richardson JL, Langholz B, Bernstein L, Burciaga C, Danley K, Ross RK. Stage and delay in breast cancer diagnosis by race, socioeconomic status, age and year. Br J Cancer. 1992;65:922-926.
120. Wells BL, Horm JW. Stage at diagnosis in breast cancer: race and socioeconomic factors. Am J Public Health. 1992; 82:1383-1385.
121. Breen N, Figueroa JB. Stage of breast and cervical cancer diagnosis in disadvantaged neighborhoods: a prevention policy perspective. Am J Prev Med. 1996;12:319-326.
122. Campbell RJ, Ferrante JM, Gonzalez EC, Roetzheim RG, Pal N, Herold A. Predictors of advanced stage colorectal cancer diagnosis: results of a population-based study. Cancer Detect Prev. 2001;25:430-438.
123. Kaffashian F, Godward S, Davies T, Solomon L, McCann J, Duffy SW. Socioeconomic effects on breast cancer survival: proportion attributable to stage and morphology. Br J Cancer. 2003;89:1693-1696.
124. Riley GF, Potosky AL, Lubitz JD, Brown ML. Stage of cancer at diagnosis for Medicare HMO and fee-for-service enrollees. Am J Public Health. 1994;84:1598-1604.
125. Ayanian JZ, Kohler BA, Abe T, Epstein AM. The relation between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med. 1993;329: 326-331.
126. Miller BA, Kolonel LN, Bernstein L, et al. Racial/ethnic patterns of cancer in the United States 1988-1992. Bethesda, MD: National Cancer Institute, 1996.
127. Deapen D, Liu L, Perkins C, Bernstein L, Ross RK. Rapidly rising breast cancer incidence rates among Asian-American women. Int J Cancer. 2002;99:747-750.
128. Trapido EJ, Burciaga Valdez R, Obeso JL, Strickman-Stein N, Rotger A, Perez-Stable EJ. Epidemiology of cancer among Hispanics in the United States. J Natl Cancer Inst Monograph 1995;18:17-28.
129. Wolfgang PE, Semeiks PA, Burnett WS. Cancer incidence in New York City Hispanics, 1982 to 1985. Ethn Dis. 1991;1: 263-272.
130. Friedell GH, Ross FE, Tucker TC, et al. Cervical cancer in Kentucky. J Ky Med Assoc. 2000;98:398-405.
131. Bureau of Indian Affairs. Available from URL: http://www. doi.gov/bureau-indian-affairs.html [accessed on February 27, 2004].
132. Haynes MA, Smedley BD. The unequal burden of cancer: an assessment of NIH research and programs for ethnic minorities and the medically underserved. Washington, DC: National Academy Press, 1999.
133. Sugarman JR, Holliday M, Ross A, Castorina J, Hui Y. Improving American Indian cancer data in the Washington State Cancer Registry using linkages with the Indian Health Service and tribal records. Cancer. 1996;78:1564-1568.
134. Poe GS, Powell-Griner E, McLaughlin JK, Placek PJ, Thompson GB, Robinson K. Comparability of the death certificate and the 1986 National Mortality Followback Survey. Vital Health Stat 2. 1993;(118):1-53.
135. Rosenberg HM, Maurer JD, Sorlie PD, et al. Quality of death rates by race and Hispanic origin: a summary of current research, 1999. Vital Health Stat 2. 1999;(128):1-13.
136. Characteristics of the SEER population compared with the total United States population. Available from URL: http:// www.seer.cancer.gov/registries/ characteristics.html [accessed February 27, 2004].
137. Curry SJ, Byers T, Hewitt M. Fulfilling the potential of cancer prevention and early detection. Washington, DC: The National Academies Press, 2003.
138. Institute of Medicine National Research Council. Ensuring quality cancer care. In: Hewitt M, Simone JV, editors. National Cancer Policy Board, Institute of Medicine and Commission on Life Sciences, National Research Council. Washington, DC: National Academy Press, 1999:246.
139. Lipscomb J, Donaldson MS. Outcomes research at the National Cancer Institute: measuring, understanding, and improving the outcomes of cancer care. Clin Ther. 2003;25: 699-712.
140. Centers for Disease Control and Prevention. Implementing recommendations for the early detection of breast and cervical cancer among low income women. MMWR Morb Mortal Wkly Rep. 2000;49:37-50.
141. U.S. Department of Health and Human Services. The Nation's investment in cancer research. A plan and budget proposal for Fiscal Year 2005. Bethesda, MD: National Cancer Institute, 2003.